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Abstract
Background The economic evaluation of treatments usually requires access to individual patient data, which is difficult to 
obtain. Moreover, in osteoarthritis, health utility scores are unavailable and can be assessed only using a validated equa-
tion model based on various clinical data. We aimed to develop and validate a methodology to simulate individual health 
utility scores from aggregated clinical data available in published studies to calculate the cost-effectiveness of different 
glucosamine preparations (i.e., crystalline glucosamine sulfate, glucosamine sulfate, and glucosamine hydrochloride) used 
for osteoarthritis.
Methods We developed a method to simulate individual utility values and validated the model by comparing the results 
obtained with the simulation and the results of one trial where the utility scores are available. Then, we simulated the utility 
scores of 10 published trials that used different glucosamine preparations. The utility estimates were used to calculate the 
quality-adjusted life year (QALY) using the area-under-the-curve method. Costs were for the glucosamine product only. The 
incremental cost/effectiveness ratio (ICER) was then calculated.
Results The values of utility scores calculated from data sources and those simulated with the model were similar. From 10 
studies where utility was simulated, four used crystalline glucosamine sulfate, and six used other formulations. The ICER 
revealed that compared to placebo, crystalline glucosamine sulfate only was cost-effective at all time points and up to 3 years 
with a median ICER of 5347.2 €/QALY at month 3, 4807.2 €/QALY at month 6 and 11535.5 €/QALY at year 3. The use of 
other formulations was not cost-effective.
Conclusion Using a new model to simulate individual health utility scores of patients included in ten published trials, ICER 
analysis showed that the use of crystalline glucosamine sulfate is cost-effective, while other formulations were not. The 
results confirm the importance of the formulation of glucosamine products.
Keywords Osteoarthritis · Cost-effectiveness · Glucosamine
Introduction
Osteoarthritis (OA) is a major public health problem because 
of its current and future prevalence, its impact on mortality 
and morbidity and the associated healthcare cost [1]. Phar-
macological and non-pharmacological treatments are cur-
rently available and their effects in reducing the symptoms 
of OA or increasing the quality of life of OA patients have 
been widely assessed by different scientific organisations 
[2–4]. A treatment algorithm for the management OA was 
also proposed, which provides practical guidance for the 
prioritisation of interventions [5]. In this algorithm, the use 
of symptomatic slow-acting drugs for osteoarthritis (SYSA-
DOA) as the first pharmacological therapy is recommended. 
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However, some international scientific societies do not rec-
ommend the use of SYSADOAS in their most recent guide-
lines [2, 4, 6]. Indeed, there are many different agents in the 
class of SYSADOAs, including glucosamine, chondroitin, 
diacerein, and avocado soybean unsaponifiables, and not all 
are supported with a high level of clinical efficacy data, nor 
supported by the same degree of recommendation in clini-
cal guidelines. Although more studies are needed to further 
substantiate their precise effects, some evidence is available 
with the use of glucosamine and chondroitin as SYSADOAs 
with an impact on both symptoms and structure in the long 
term. Multiple formulations of glucosamine and chondroitin 
are available as both prescription-grade products and nutri-
tional supplements, and these differences have been hypoth-
esised as being an important driver of the discrepancy in the 
level of recommendation of SYSADOAS between guidelines 
[7]. Indeed, although all preparations may claim to have a 
therapeutic effect, not all are supported by clinical evidence 
[8]. For example, with glucosamine, an independent meta-
analysis has shown that in trials using a specific formulation 
of glucosamine, the prescription crystalline glucosamine 
sulfate (pCGS) had a better outcome on pain than did other 
preparations of glucosamine [9].
In a world with limited resources and health care budgets, 
it is important to allocate scarce resources efficiently and 
consequently, to develop effective treatments and efficient 
strategies. Economic evaluation is a method for compar-
ing different strategies in terms of cost (e.g., intervention 
costs and disease costs) and consequences [e.g., life years or 
quality-adjusted life year (QALY)]. These evaluations play 
a growing role in pricing and reimbursement decisions as 
regulatory agencies rely more and more on pharmacoeco-
nomic data to make decisions about limited resources [10]. 
To the best of our knowledge, only one clinical trial has 
explored the cost-effectiveness of glucosamine (and in this 
particular case the pCGS formulation) compared with that of 
paracetamol and placebo in the treatment of knee OA [11]. 
The authors concluded that compared with paracetamol and 
placebo, pCGS was a highly cost-effective therapy to treat 
patients diagnosed with knee OA. However, another research 
group using a cohort simulation model based on clinical 
data available from five systematic reviews and one clinical 
guideline showed that there was evidence that glucosamine 
sulfate shows some clinical effectiveness in the treatment of 
OA of the knee [12]. However, in this economic evaluation 
the authors highlighted the need for further research since 
they showed that estimates were imprecise and subject to a 
degree of decision uncertainty.
To further advance the economic evaluation of glucosa-
mine, we should theoretically have access to individual 
patient data. Unfortunately, most of the time, access to these 
data is not possible because of technical, legal or patient 
willingness issues. Consequently, we decided to develop and 
validate a method to simulate individual health utility scores 
based on the aggregated clinical data provided in published 
papers of clinical trials. Based on this method of simulation, 
we performed some cost-effectiveness analyses based on tri-
als that used different formulations of glucosamine.
Materials and methods
Development of the simulation model
To simulate individual values, we had to solve two major 
issues. The first issue is that health utility scores are not 
directly assessed in most OA studies in contrast to WOMAC 
(i.e., an OA specific health-related quality of life question-
naire) scores. Interestingly, Grootendorst et al. [13] have 
developed a linear regression model to estimate utility scores 
based on the age of the patient, the number of years since he/
she was diagnosed with OA and the three different WOMAC 
subscales scores. The second issue is that only summary 
statistics (mean, median, standard deviation, covariance or 
confidence interval) of age, number of years since OA and 
WOMAC scores are reported in most OA trials.
To overcome these issues, we propose the following pro-
cedure to obtain individual health utility scores:
• Use the SIMNORMAL procedure of SAS and published 
summary statistics to simulate individual values for the 
WOMAC indexes, age and years since OA. The SIM-
NORMAL procedure performs conditional and uncondi-
tional simulation for a set of correlated normal or Gauss-
ian random variables.
• Discard simulated values outside the following permis-
sible ranges: 0–20 for pain, 0–68 for function, 0–8 for 
stiffness, 0–100 for age and 0–100 for years since OA 
diagnosis.
• Compute individual female utility scores from the equa-
tion provided in the paper by Grootendorst (considering 
that the parameter “female” in the equation of Grooten-
dorst takes the value of 1 if the patient is a woman).
To validate the procedure, we tested it on data from the 
only study on glucosamine in which individual health utility 
values were published [11] and for which we have access 
to the individual values for WOMAC scores, age and years 
since OA diagnosis, at baseline and after 3 months of treat-
ment. We computed means and standard deviations for and 
between these values with the CORR procedure of SAS at 
baseline, after 3 months and for subjects in the placebo and 
pCGS groups. Next, we compared simulated and published 
values.
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Simulation of individual health utility scores
We used the procedure to simulate individual health util-
ity scores for all clinical trials cited in the meta-analysis of 
Eriksen et al. [9] that have used the WOMAC. Consequently, 
we simulated individual health utility scores from ten trials 
(4 using pCGS and 6 using other forms of glucosamine) 
[14–23]. When available, means and SD were extracted 
from published articles, after correction for the scales (to 
be on the scale for WOMAC indexes as the one used in the 
equation of Grootendorst). We replaced missing data in the 
summary statistic of published studies (i.e., sometimes data, 
such as the standard deviation or a specific variable such 
as years since OA, were unavailable) with data from the 
study used to develop and validate the procedure [11]. We 
simulated a total of 20,000 patients in each study (10,000 
glucosamine and 10,000 placebo), and data were examined 
by two independent experts.
QALY assessment
The utility estimates were used to calculate the QALY using 
the area-under-the-curve method [24] that is the weighted 
average of time spent in the study and utility value. If more 
than one study was available for a particular time (e.g., 3 
months), we weighted each study according to the number 
of subjects included in the trial.
Costs of glucosamine
Since there are major differences in products, reimbursement 
strategies, daily dosage, among other factors, the range of 
costs of glucosamine products varies widely. To get an offi-
cial overview, we could access the official IMS Health data, 
updated at December 2017, related to the main selling prices 
of the different formulations, in the different countries. Since 
the data is reported in both local currency and US dollars, it 
was possible to report data in US dollars and then in Euros 
with homogeneous currency exchange rate. Obviously, we 
separated pCGS and other forms of glucosamine. Since the 
price range was quite wide, to reduce variability and define a 
reasonably weighted average price for each of the two forms 
of glucosamine, the following methodology was devised: 
after calculation of the overall average price, all prices that 
were > 50% lower than this average price were excluded, and 
the new average of the remaining prices was calculated and 
defined as the “higher” value of the cost-range. In the same 
way, we started again with all prices and excluded those that 
were > 50% higher than the overall average, and calculated 
a new average of the remaining prices, which was defined 
as the “lower” value of the price range. Consequently, we 
achieved a median cost of 0.79 €/day for pCGS (with low 
and high prices of 0.65 €/day and 0.88 €/day, respectively) 
and a median cost of 0.55 €/day for other forms of glucosa-
mine (with low and high prices of 0.45 €/day and 0.66 €/
day, respectively). The price of placebo was considered 0 €.
Cost‑effectiveness analysis
The incremental cost/effectiveness ratio (ICER)—a meas-
ure of the additional cost per unit of health gain—was then 
calculated. The underlying calculation for the ICER com-
paring glucosamine products vs. placebo in patients with 
knee OA was equal to (average cost glucosamine − average 
cost placebo)/(average effect glucosamine − average effect 
placebo) where costs were measured in Euros, and effects 
were measured in QALY.
Sensitivity analysis
Because of the different time points used in different stud-
ies (i.e., from 2 months to 3 years), we decided to use data 
from longer studies at all time points. For example, for a 
3-year study, we considered an 8.3% of the global effect at 
month 3 (3/36 × 100 = 8.3%) and a 16.7% of the global effect 
at month 6 (6/36 × 100 = 16.7). Obviously, we acknowledge 
that this approach could reduce the potential (cost)-effective-
ness of the treatment since it has been shown that at least 3 
months is needed to begin seeing an effect with most of the 
SYSADOAs.
Results
From the study of Herrero-Beaumont et al. [16], the simu-
lated mean health utility score was 0.598 at baseline and 
0.676 at the end of the study in the glucosamine group. 
These values were respectively 0.602 and 0.651 in the pla-
cebo group. The change over time was 0.08 in the glucosa-
mine group and 0.05 in the placebo group. Interestingly, 
these values are completely similar to the previously pub-
lished results (i.e., 0.59 and 0.60 at baseline and a 0.08 and 
0.05 change over time in the glucosamine group and the 
placebo group, respectively) suggesting that the simulation 
model provides reliable utility value [11].
The differences between the glucosamine and placebo 
groups in the changes over time of the simulated utility 
scores of all clinical trials that have used the WOMAC are 
presented in Table 1. As expected from previously published 
WOMAC results [9], the differences in changes in utility 
values were more often in favour of glucosamine in trials 
that used pCGS than in those that used other formulations.
The evolution of the health utility scores among studies 
that used pCGS or other forms of glucosamine is presented 
in Fig. 1. The utility score always improved when pCGS was 
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used while the results are much more variable when other 
formulations of glucosamine were used.
The calculation of the ICER among studies having used 
pCGS show that the use of this formation is highly cost-
effective compared to placebo, regardless of the price of the 
treatment (Table 2). The ICER calculation also shows that 
pCGS is already cost-effective after 3 months of treatment 
and up to 3 years after the initiation of the treatment.
When looking at other forms of glucosamine, notably, if the 
ICER results could be considered cost-effective at 2 months 
(based on one single study), the results no longer show the 
cost-effectiveness of these other formulations of glucosamine 
at 3 months (Table 3). Moreover, at 6 months of treatment, 
from a health economics perspective, placebo is even better 
than these formulations. None of these results are substantially 
influenced by the costs of glucosamine.
The results of sensitivity analyses, using data from longer 
studies at all time points, are presented in Fig. 2 and Tables 4 
and 5. For pCGS, the health utility change is always in favour 
of the treatment compared to placebo and the ICER shows a 
cost-effectiveness that increases over time. Using other for-
mulations of glucosamine, no meaningful difference in utility 
scores is observed compared to placebo and the cost-effec-
tiveness analyses confirm the absence of economic interest of 
these formations at all time points.
Table 1  Health utility changes in the studies using pCGS or other forms of glucosamine
Type of glucosamine N Duration 
(month)
Health utility changes in the 
glucosamine group
Health utility changes 
in the Placebo group
Giordano et al. [17] pCGS 60 3 0.135 − 0.0742
Beaumont et al. [16] pCGS 210 6 0.0785 0.0315
Reginster et al. [14] pCGS 212 36 0.1606 0.1427
Pavelka et al. [15] pCGS 202 36 0.0487 0.0207
Houpt et al. [18] Other form of glucosamine 101 2 0.0293 0.0129
McAlindon et al. [19] Other form of glucosamine 205 3 − 0.0465 − 0.0339
Frestedt et al. [22] Other form of glucosamine 35 3 0.1629 0.0613
Chopra et al. [25] Other form of glucosamine 70 3 0.0016 0.1232
Cibere et al. [20] Other form of glucosamine 137 6 0.0096 0.0006
Clegg et al. [21] Other form of glucosamine 630 6 0.0242 0.0383
Fig. 1  Health utility evolution 
in trials having used pCGS or 






















Table 2  Incremental cost-effectiveness ratio results of studies having 
used pCGS
At 3 months At 6 months At 36 months
QALY change pCGS 0.016875 0.0435625 0.27418931
QALY change placebo − 0.009275 − 0.0146125 0.12872929
Median cost pCGS 139.83 279.66 1677.96
Median ICER 5347.2 4807.2 11535.5
Lowest cost pCGS 115.05 230.1 1380.6
Lowest ICER 4399.61759 3955.30726 9491.2675
Highest cost pCGS 155.76 311.52 1869.12
Highest ICER 5956.40535 5354.87752 12849.716
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Discussion
In this study, we developed a model that could simulate 
individual patient data based on aggregated data found in 
published scientific papers. Indeed, most of the economic 
analyses require an access to individual patient data, which 
is unfortunately very difficult. Our model simulated all data 
needed to calculate the utility score (i.e., age, years since 
OA diagnosis, and WOMAC subscales). Using one valida-
tion study, our simulation model was able to provide sum-
marised data similar to what could be found in the literature 
in term of utility score. It is also interesting to note that the 
Table 3  Incremental cost-
effectiveness ratio results of 
studies having used other forms 
of glucosamine
At 2 months At 3 months At 6 months
QALY change other glucosamine 0.002344 0.00303613 0.00423555
QALY change placebo 0.001032 0.0020409 0.00752699
Median cost other glucosamine 33 49.5 99
Median ICER 25,152.4 49,737.4 Placebo better
Lowest cost other glucosamine 27 40.5 81
Lowest ICER 20,579.2 40,694.2 Placebo better
Higesth cost other glucosamine 39.6 59.4 118.8
Highest ICER 30,182.9 59,684.9 Placebo better
Fig. 2  Health utility score evo-
lution using data from longer 
studies at all time points among 























Table 4  Incremental cost-effectiveness ratio results of studies that 
used pCGS–sensitivity analyses
At 3 months At 6 months At 36 months
QALY change pCGS 0.00365489 0.01207722 0.19225352
QALY change placebo 0.00031524 0.00310523 0.13181955
Median cost pCGS 139.83 279.66 1677.96
Median ICER 41,869.6 31,170.3 27,765.1
Lowest cost pCGS 115.05 230.1 1380.6
Lowest ICER 34,449.7143 25,646.468 22,844.7678
Higesth cost pCGS 155.76 311.52 1869.12
Highest ICER 46,639.6132 34,721.3721 30,928.301
Table 5  Incremental cost-
effectiveness ratio results of 
studies that used other forms 
of glucosamine–sensitivity 
analyses
At 2 months At 3 months At 6 months
QALY change other glucosamine 0.0004075 0.00056492 0.00311919
QALY change placebo 0.00080951 0.00140589 0.00595049
Median cost other glucosamine 33 59.4 118.8
Median ICER Placebo better Placebo better Placebo better
Lowest cost other glucosamine 27 40.5 81
Lowest ICER Placebo better Placebo better Placebo better
Highest cost other glucosamine 39.6 59.4 118.8
Highest ICER Placebo better Placebo better Placebo better
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utility score calculated with the simulation model is within 
the range observed in patients with osteoarthritis [26].
With the individual patient data simulated from ten ran-
domised controlled trials, we were able to calculate the ICER 
of different formulations of glucosamine. Our results showed 
that the use of pCGS only was cost-effective compared to 
placebo. To the best of our knowledge, only one clinical trial 
has been conducted, to assess, in post hoc analysis, the cost-
effectiveness of glucosamine. Using data form the GUIDE 
study, Scholtissen et al. showed that the use of pCGS was 
cost-effective compared to placebo but also to paracetamol 
[11]. However, one other study has assessed the health care 
utilisation following the use of pCGS [27]. In that particular 
8-year observational study following a 3-year randomised 
controlled trial, the authors showed that patients formerly 
on pCGS had recurred with less symptomatic medications 
and the use of other health resources than did those from the 
placebo group during the last year of follow-up.
In this study, we also confirm the difference of (cost-)
effectiveness among different glucosamine preparation. 
Indeed, our results highlight that pCGS, but not the other 
formulations of glucosamine is cost-effective. These results 
are supported by the recent meta-analysis of Eriksen et al. 
showing that the reduction of pain and the improvement in 
function was observed only with pCGS and not with the 
other types of glucosamine [9]. Glucosamine exists in dif-
ferent forms. However, all these products have not been 
characterised in the same way in terms of quality, pharma-
cokinetics and equivalence of human biological fluid levels 
with mechanistic data [28].
We have to acknowledge major limitations in our study. 
First, our simulation model has been validated using data 
from a single study only. Second, we did not have access 
to raw data to perform the ICER evaluation. Third, the cost 
evaluation was limited to the cost of the treatment and other 
costs have to be included to achieve a full health economics 
evaluation (e.g., the health care resources, the patient and 
family resources, the productivity costs and the others sec-
tors resources). Fourth, some data needed to calculate the 
utility were unavailable in some publications, and we had to 
replace these data by data from the trial used to validate the 
model. Fifth, we had no direct assessment of the utility score 
and had to use the regression model developed and validated 
by Grootendorst et al. to obtain an estimation of the utility 
based on the WOMAC data [13], which is only one of the 
tools to assess quality of life in musculoskeletal health [29].
In conclusion, we confirm the superiority of pCGS over 
the other glucosamine formulations in terms of efficacy 
and cost-effectiveness. These results should be confirmed 
in other studies taking into account compliance to therapy, 
the other costs of OA management and a direct assessment 
of utility.
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